Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well glembatumumab vedotin works in treating patients with
middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the
body (metastatic) or has returned at or near the same place after a period of time during
which the cancer could not be detected (locally recurrent). Glembatumumab vedotin may shrink
the tumor by binding to tumor cells and delivering tumor-killing substances to them.